Conversely, pre‐treatment eosinophilia appears to be associated with better outcomes in retrospective analyses of anti‐PD1‐ [21] and anti‐CTLA4‐treated [22, 23] melanoma and anti‐PD1‐treated NSCLC patients [24], and lower neutrophil‐to‐eosinophil ratio correlated with outcomes for combination anti‐PD1/anti‐CTLA4‐treated metastatic RCC patients [25]. The gene discussed is CTLA4; the disease is melanoma.